Why do sub-Saharan Africans present late for HIV care in Switzerland?


Journal

HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392

Informations de publication

Date de publication:
07 2019
Historique:
accepted: 18 01 2019
pubmed: 8 5 2019
medline: 14 5 2020
entrez: 8 5 2019
Statut: ppublish

Résumé

Late presentation (LP) to HIV care disproportionally affects individuals from sub-Saharan Africa (SSA). We explored the reasons for late presentation to care among this group of patients in the Swiss HIV Cohort Study. The prevalence of LP was compared between patients from Western Europe (WE) and those from SSA enrolled between 2009 and 2012. Patients were asked about HIV testing, including access to testing and reasons for deferring it, during face-to-face interviews. The proportion of LP was 45.8% (435/950) among patients from WE, and 64.6% (126/195) among those from SSA (P < 0.001). Women from WE were slightly more likely to present late than men (52.6% versus 44.5%, respectively; P = 0.06), whereas there was no sex difference in patients from SSA (65.6% versus 63.2%, respectively; P = 0.73). Compared with late presenters from WE, those from SSA were more likely to be diagnosed during pregnancy (9.1% versus 0%, respectively; P < 0.001), but less likely to be tested by general practitioners (25.0% versus 44.6%, respectively; P = 0.001). Late presenters from SSA more frequently reported 'not knowing about anonymous testing possibilities' (46.4% versus 27.3%, respectively; P = 0.04) and 'fear about negative reaction in relatives' (39.3% versus 21.7%, respectively; P = 0.05) as reasons for late testing. Fear of being expelled from Switzerland was reported by 26.1% of late presenters from SSA. The majority of patients from SSA were late presenters, independent of sex or education level. Difficulties in accessing testing facilities, lack of knowledge about HIV testing and fear-related issues are important drivers for LP in this population.

Identifiants

pubmed: 31062497
doi: 10.1111/hiv.12727
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

418-423

Subventions

Organisme : SHCS, supported by the Swiss National Science Foundation
ID : 33CSC0-108787, SHCS project number 592
Pays : International
Organisme : Ambizione-PROSPER fellowship from the Swiss National Science Foundation
ID : PZ00P3_154730
Pays : International

Investigateurs

V Aubert (V)
M Battegay (M)
E Bernasconi (E)
J Böni (J)
D L Braun (DL)
H C Bucher (HC)
A Calmy (A)
M Cavassini (M)
A Ciuffi (A)
G Dollenmaier (G)
M Egger (M)
L Elzi (L)
J Fehr (J)
J Fellay (J)
H Furrer (H)
C A Fux (CA)
H F Günthard (HF)
D Haerry (D)
B Hasse (B)
H H Hirsch (HH)
M Hoffmann (M)
I Hösli (I)
C Kahlert (C)
L Kaiser (L)
O Keiser (O)
T Klimkait (T)
R D Kouyos (RD)
H Kovari (H)
B Ledergerber (B)
G Martinetti (G)
B Martinez de Tejada (B)
C Marzolini (C)
K J Metzner (KJ)
N Müller (N)
D Nicca (D)
G Pantaleo (G)
P Paioni (P)
A Rauch (A)
C Rudin (C)
A U Scherrer (AU)
P Schmid (P)
R Speck (R)
M Stöckle (M)
P Tarr (P)
A Trkola (A)
P Vernazza (P)
G Wandeler (G)
R Weber (R)
S Yerly (S)

Informations de copyright

© 2019 British HIV Association.

Auteurs

A Hachfeld (A)

Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.

K Darling (K)

Department of Infectious Diseases, University Hospital Lausanne, Lausanne, Switzerland.

A Calmy (A)

Department of Infectious Diseases, University Hospital Geneva, Geneva, Switzerland.

B Ledergerber (B)

Department of Infectious Diseases, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

R Weber (R)

Department of Infectious Diseases, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

M Battegay (M)

Department of Infectious Diseases, University Hospital Basel and University of Basel, Basel, Switzerland.

K Wissel (K)

Department of Infectious Diseases, Cantonal Hospital, St. Gallen, Switzerland.

C Di Benedetto (C)

Department of Infectious Diseases, Regional Hospital, Lugano, Switzerland.

C A Fux (CA)

Department of Infectious Diseases, Cantonal Hospital Aargau, Aargau, Switzerland.

P E Tarr (PE)

Department of Infectious Diseases, Kantonsspital Baselland and University of Basel, Basel, Switzerland.

R Kouyos (R)

Department of Infectious Diseases, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Institute of Medical Virology, University of Zurich, Zurich, Switzerland.

L S Ruggia (LS)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

H J Furrer (HJ)

Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.

G Wandeler (G)

Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH